SuperworthFortress Biotech FBIO
- Market cap
- $64.4M
- PE
- n/m
- not a meaningful number
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $34.8M+110% | $19.9M+22% | $13M+5% | $14.9M−14% | $14.6M−58% | $15.1M−24% | $13.1M+1% | $16.4M+10% | $17.6M+21% | n/a | $16M+22% | $18.7M+14% | |
| Cost of revenue | $6.4M−11% | $6M−22% | $6M−7% | $5.7M−26% | $4.5M−31% | $2.2M−63% | $4.8M−20% | $4.9M−14% | $5.8M+29% | n/a | $6.2M+30% | $6.1M+24% |
| Gross profit | $28.3M+204% | $13.9M+60% | $7M+18% | $9.2M−5% | $10.2M−64% | $12.9M−8% | $8.3M+19% | $11.5M+25% | $11.9M+17% | n/a | $9.8M+18% | $12.6M+10% |
| R&D | $20.3M−32% | $14M−59% | $24.8M−30% | $12.7M−61% | $9.4M−53% | $9.7M−31% | $3.9M−84% | $8.1M−36% | $208K−98% | n/a | $540K−86% | $805K−90% |
| SG&A | $21.7M−28% | $22.6M−20% | $17.9M−29% | $20.8M−15% | $22M+1% | $26.9M+19% | $25.7M+43% | $38.8M+86% | $17.4M−21% | n/a | $15.9M−38% | $20.8M−46% |
| −$13.8M−73% | −$19.6M−64% | −$36.6M−38% | −$27.8M−45% | −$22.1M+61% | −$23.8M+22% | −$22.3M−39% | −$36.5M+31% | −$6.8M−69% | n/a | −$7.7M−65% | −$10M−73% | |
| Interest expense | $2.5M−25% | $2.1M−57% | $2.6M−39% | $2.1M−67% | $6.2M+145% | $2.6M+26% | $2.8M+8% | $2.5M+19% | $2.7M−56% | n/a | $3.4M+20% | $1.5M−41% |
| Pre-tax income | −$10.6M−80% | −$28.6M−50% | n/a | n/a | −$26.6M+152% | −$26M−9% | −$24.7M | −$11.7M | $8.9M | n/a | $142.3M | $922K |
| $141K | $379K−16% | n/a | n/a | $69K−51% | $336K−11% | $0 | n/a | $26K−62% | n/a | $5.1M | $320K | |
| Net income | −$5M−78% | −$9.3M−66% | −$15.4M−28% | −$10.9M−56% | −$12.9M+155% | −$6.8M−27% | −$10.6M−31% | $15.5M | $5.8M | −$3.9M−42% | $110.4M | −$468K |
| −$0.94−77% | −$1.05−77% | −$1.04−70% | −$0.73−80% | −$0.76−19% | −$0.37−65% | −$0.48−54% | $0.45 | $0.11 | −$0.20−46% | $2.82 | −$0.08 | |
| 7.5M+26% | 10.7M+78% | 17.2M+153% | 18.3M+148% | 19.7M+163% | 26M+142% | 26.5M+54% | 29.8M+63% | 33.1M+68% | 30.4M+17% | 38.4M+45% | 31.8M+7% |
Gross profit: 38 periods, Q4 FY15 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Fortress Biotech's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| FBIOFortress Biotech | $64.4M | n/m | n/a | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| Peer median | $477.3M | 10.5× | 12.3× | 1.4× | +2% | 13.6% |
More on Fortress Biotech
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .